Pembrolizumab-induced Stevens–Johnson syndrome in non-melanoma patients

Pembrolizumab is an anti-PD1 monoclonal antibody initially used in metastatic melanoma which has also been found to be active in other cancer types. Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but potentially fatal complications of anti-PD-1 therapy. To our knowledge, there have been 2 cases of nivolumab-induced TEN [1,2] and 1 case of SJS after radiotherapy with anti-PD-1 therapy [3] in patients with metastatic melanoma reported in literature. We present 2 cases of pembrolizumab-induced SJS, which we believe is the first case report in non-melanoma patients.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2p1FqBv
via IFTTT